**Company Overview**

**Company Background**

- A leading biotech company founded in 2013 by world-class scientists and experienced businessmen
- Capitalizing on the extensive knowledge of human diseases and proteomics amongst its founders and collaborators
- Focusing on innovative peptide drugs using protected platform technology
  - Platform 1: Peptide Array
  - Platform 2: Peptide-mediated Protein Knockdown Technology
- Has identified a series of key domains of disease-related proteins and designed many effective lead compounds
- Patents filed nationally and internationally for 4 lead compounds and 1 platform technology

**World-class Founders**

- **Dr. Max S. Cynader**, CM, OBC, PhD, FRSC, FCAHS: Founder of 4 start-ups; First company, NeuroVir, was sold to Medigene AG for 140 million
- **Dr. Yu Tian Wang**, MD, PhD, FRSC: Co-founder of NoNO Inc, a peptide therapeutics company with a peptide product currently in phase 3 clinical trial
- **Dr. William Jia**, MSc, PhD: Founder and CSO of several high-tech companies

**Verified Platform Technology**

- With the same platform technologies, one of the company founders has previously designed a peptide drug that is similar to our company’s current patented lead compounds: similar design, similar size, similar drug characteristics, but different targets
- The peptide drug has now entered a phase 3 clinical trial in Canada and the US

**Successful Experience**

- Yabao Pharmaceutical Co, Inc. (Shanghai Stock Exchange 600351), a leading pharmaceutical company in China, has signed an exclusive license with privately held Primary Peptides, Inc., to develop and commercialise the innovative product K13 targeting PTEN nuclear translocation for the treatment of stroke
- Plan to file IND in 2017 for clinical trials in both Australia and China
Focusing on severe diseases with large drug markets

Cardiovascular Diseases
- Heart attack
- Stroke

Brain Diseases
- Parkinson’s disease
- Huntington’s disease

Cancer
- Prostate cancer
- Pancreatic cancer

Lead Compound Characteristics

Drug Category
- **US FDA**: Biotechnology-Derived Pharmaceuticals
- **China CFDA**: Chemical Drug Type 1.1: Synthetic or semi-synthetic chemical drug that is not on the market anywhere

Drug Advantages
- Low toxicity, high specificity, able to cross the blood-brain barrier

Drug Form
- Dry peptide powder

Drug Source
- Chemical synthesis
Respected and experienced founders

Have signed an exclusive licensing deal with a major Chinese pharmaceutical company

Robust patent position plus trade secrets

Disruptive, scalable technologies applied to major diseases. Lead compounds already developed and optimized

Launch preclinical studies of 6 lead compounds in 3 years; Expect 2 drugs in clinical trials in 2 years

Large opportunities. Platform technology allows us to rapidly develop plausible leads in new diseases and for new targets

Globally integrated R&D capabilities and a robust and growing product pipeline
Primary Peptides is looking for 1) additional pharma/biotech partners for drug development and 2) potential investors

If you have any questions, feel free to contact us:

Dr. Max S. Cynader, CM, OBC, PhD, FRSC, FCAHS  
Co-founder  
Office: (+1) 604-822-0395  
Mobile: (+1) 604-649-2274  
Email: cynader@brain.ubc.ca  
2211 Wesbrook Mall,  
Vancouver, BC, Canada, V6T 2B5  
www.primarypeptides.com